Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: erlotinib hydrochloride
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2008-04-18

Last Posted Date: 2020-02-20

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 59

Registration Number: NCT00661193

Locations: 🇺🇸
Harborview Medical Center, Seattle, Washington, United States
🇺🇸
Minor and James Medical, PLLC, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

and more 121 locations

Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer

Phase 2

Completed

Conditions: Cholangiocarcinoma
Gallbladder Cancer

Interventions: Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2008-04-17

Last Posted Date: 2013-08-13

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 49

Registration Number: NCT00660140

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer

Phase 3

Active, not recruiting

Conditions: Ovarian Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2008-04-17

Last Posted Date: 2023-03-24

Lead Sponsor: National Cancer Institute, Naples

Target Recruit Count: 800

Registration Number: NCT00660842

Locations: 🇮🇹
Ospedale S. Giovanni Calibita Fatebenefratelli, UO di Oncologia, Roma, Italy
🇮🇹
A.O. Univeristaria Policlinico, Modena, Italy
🇮🇹
Ospedale Civile S. Spirito, Pescara, Italy

and more 25 locations

Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval

Phase 3

Active, not recruiting

Conditions: Ovarian Cancer

Interventions: Drug: stealth liposomal doxorubicin
Drug: carboplatin
Drug: paclitaxel
Drug: Topotecan
Drug: Gemcitabine

First Posted Date: 2008-04-14

Last Posted Date: 2023-11-13

Lead Sponsor: National Cancer Institute, Naples

Target Recruit Count: 215

Registration Number: NCT00657878

Locations: 🇮🇹
Universita Cattolica del Sacro Cuore, Roma, Italy
🇮🇹
Ospedale Mazzoni, Ascoli Piceno, Italy
🇮🇹
Ospedale Senatore Antonio Perrino, Brindisi, Italy

and more 35 locations

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: bevacizumab
Drug: Carboplatin
Drug: ABI-007

First Posted Date: 2008-04-09

Last Posted Date: 2017-09-14

Lead Sponsor: Loyola University

Target Recruit Count: 32

Registration Number: NCT00654836

Locations: 🇺🇸
Delnor Community Hospital - Geneva, Geneva, Illinois, United States
🇺🇸
Swedish-American Regional Cancer Center, Rockford, Illinois, United States
🇺🇸
Good Samaritan Cancer Care Center at Advocate Good Samaritan Hospital, Downers Grove, Illinois, United States

and more 3 locations

A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Tumors

Interventions: Drug: Carboplatin
Drug: Fosbretabulin
Drug: Paclitaxel
Drug: Bevacizumab

First Posted Date: 2008-04-07

Last Posted Date: 2015-02-09

Lead Sponsor: Mateon Therapeutics

Target Recruit Count: 63

Registration Number: NCT00653939

Locations: 🇺🇸
Pacific Coast Hematology and Oncology Medical Group, Fountain Valley, California, United States
🇺🇸
The Mark H. Zangmeister Center, Columbus, Ohio, United States
🇺🇸
Southbay Oncology Hematology, Campbell, California, United States

and more 12 locations

Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Peritoneal Cavity Cancer
Ovarian Cancer

First Posted Date: 2008-04-04

Last Posted Date: 2019-04-08

Lead Sponsor: Mayo Clinic

Target Recruit Count: 48

Registration Number: NCT00652691

Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

Phase 3

Completed

Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carboplatin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Etoposide
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Methotrexate
Drug: Thiotepa
Drug: Vincristine Sulfate

First Posted Date: 2008-04-04

Last Posted Date: 2024-04-23

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 70

Registration Number: NCT00653068

Locations: 🇺🇸
Prisma Health Richland Hospital, Columbia, South Carolina, United States
🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸
Lee Memorial Health System, Fort Myers, Florida, United States

and more 91 locations

Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin

Phase 1

Conditions: Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Avastin

First Posted Date: 2008-04-03

Last Posted Date: 2020-08-19

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 46

Registration Number: NCT00652119

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

and more 2 locations

Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma

Phase 1

Terminated

Conditions: Glioblastoma Multiforme

Interventions: Drug: CYT997
Drug: Carboplatin

First Posted Date: 2008-04-02

Last Posted Date: 2013-05-03

Lead Sponsor: Gilead Sciences

Target Recruit Count: 20

Registration Number: NCT00650949

Locations: 🇦🇺
Royal North Shore Hospital, St-Leonards, New South Wales, Australia
🇦🇺
Flinders Medical Centre, Bedford Park, South Australia, Australia
🇦🇺
Gold Coast Hospital, Southport, Queensland, Australia

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy